Caisse de dépôt invests $3.2B in United Kingdom nuclear power plant
The Caisse de dépôt et placement du Québec says it plans to invest the equivalent of $3.2 billion alongside the United Kingdom government in the Sizewell C nuclear power plant project.
The $1.7 billion investment represents a 20 per cent stake in the 3.2 GW project, which is expected to supply electricity for 60 years.
The announcement comes as a surprise, as Canadian company Brookfield was expected to be the British government's main partner.
Other shareholders include French company EDF, British multinational Centrica and Amber Infrastructure.
The Caisse says it plans to invest $8 billion in the U.K. over the next five years, which would increase its investments in the country by 50 per cent.
Quebec's pension fund also recently announced its intention to invest $400 billion in companies that are decarbonizing their activities in search of climate solutions.
The Sizewell C power plant would reduce the U.K.'s dependence on hydrocarbons and cut carbon emissions by 9 million tonnes per year.
Environmentalists are divided on nuclear energy as it offers an alternative to hydrocarbons in reducing CO2 emissions, but produces radioactive waste that must be managed for many years.
This report by The Canadian Press was first published in French on July 22, 2025.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
a day ago
- Globe and Mail
Bayer AG's Exploratory Study on Sepsis and DIC: A Potential Game-Changer?
Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Bayer AG is conducting an exploratory study titled 'Exploratory Study to Investigate the Association Between the Onset of Disseminated Intravascular Coagulation (DIC) and Disease Progression With Different Biomarker Candidates as Well as Standard Clinical and Demographic Parameters in Adult Patients With Sepsis.' The study aims to understand how sepsis progresses to DIC, a severe blood disorder, by identifying biomarkers in patients admitted to intensive care units across Europe. This research is significant due to the limited treatment options for DIC, especially in sepsis patients. The study involves no investigational treatments; instead, participants receive standard medical care for sepsis. The focus is on collecting blood samples and clinical data to identify biomarkers indicative of DIC development. Designed as an interventional study with a single-group model, this research does not involve masking and primarily seeks to gather observational data. The study's primary purpose is to explore the progression of sepsis to DIC. The study began on January 29, 2025, with primary completion expected within 56 days for each participant. The latest update was submitted on July 22, 2025, indicating ongoing recruitment and data collection. This study could impact Bayer's stock performance by potentially enhancing its reputation in the medical research field, especially if the findings lead to improved understanding and treatment of sepsis-related DIC. Investors may view this as a positive development, although the absence of new drug interventions limits immediate commercial implications. The study is ongoing, with further details available on the ClinicalTrials portal.
Globe and Mail
a day ago
- Globe and Mail
AstraZeneca's New Trial: A Potential Game-Changer in Prostate Cancer Treatment
AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca, in collaboration with Parexel International, is conducting a Phase I clinical trial titled A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer. The study aims to assess the safety and tolerability of the drugs AZD2284, AZD2287, and AZD2275 in treating this aggressive form of prostate cancer. The trial is testing three drugs: AZD2284, AZD2287, and AZD2275, all administered via intravenous methods. AZD2284 is the primary focus, with the goal of determining its optimal dosing and efficacy in conjunction with the other two drugs. This non-randomized, open-label study follows a sequential intervention model. It is primarily focused on treatment, with no masking involved, allowing for direct observation of the drug effects. The study began on March 10, 2025, with the latest update submitted on July 22, 2025. These dates are crucial as they indicate the study's progress and the timeline for potential results. This study's update could influence AstraZeneca's stock performance positively, as successful results may enhance investor confidence and market position in the oncology sector. Competitors in the prostate cancer treatment market will be closely monitoring these developments. The study is currently recruiting, with further details available on the ClinicalTrials portal.
Globe and Mail
a day ago
- Globe and Mail
AstraZeneca's AZD0486 Study: A Potential Game-Changer in B-Cell Lymphoma Treatment
AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. AstraZeneca is conducting a phase 1 clinical study titled A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects With B-Cell Non-Hodgkin Lymphoma. The study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of AZD0486 in patients with B-cell non-Hodgkin lymphoma. The intervention being tested is AZD0486, a bispecific antibody designed to engage T-cells and target CD19 on tumor cells, facilitating T cell-mediated destruction of malignant B cells. It is administered intravenously in a structured dosing schedule. This interventional study follows a sequential intervention model with no masking, focusing primarily on treatment. Participants receive increasing doses of AZD0486, with safety and efficacy monitored throughout the study. The study began on March 2, 2021, and is currently recruiting. The last update was submitted on July 22, 2025. These dates are crucial for tracking the study's progress and ensuring timely updates to stakeholders. The ongoing study may influence AstraZeneca's stock performance and investor sentiment, as successful outcomes could enhance the company's oncology portfolio. Investors should also consider the competitive landscape in the B-cell lymphoma treatment market. The study is ongoing, with further details available on the ClinicalTrials portal.
